Crohn DiseaseBEST-CDNCT05521867
Endoscopic Balloon Dilation Versus Endoscopic Stricturotomy for Short Crohn's Strictures
A study testing Endoscopic balloon dilation and Endoscopic stricturotomy with or without stricturoplasty in people with Crohn Disease, run by Asian Institute of Gastroenterology, India at 1 site in India.
Trial summary
Crohn's disease (CD) related strictures can be treated endoscopically by endoscopic balloon dilation (EBD) or endoscopic stricturotomy (EST). EBD is is the established endoscopic treatment for short strictures in Crohn's disease. However, roughly half had recurrent symptoms and two third require surgery after EBD. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Crohn Disease
- What is being tested?
- Endoscopic balloon dilation and Endoscopic stricturotomy with or without stricturoplasty
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteIndia
- Study dates
- 10 Feb 2023to 9 Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- No established diagnosis of CD;
- No endoscopic therapy; and
- A combination therapy of EST and EBD at the onset
- Small bowel CD related stricture requiring enteroscopy guided dilation
- Predominantly ulcerated strictures (mixed or pure ulcerated strictures)
- Long strictures (>3 cm)
Show all 9Show fewer
- Pediatric Patients (<18 years)
- Pregnant or lactating mother
- Not willing to participate
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Randomized Controlled Trial Comparing Endoscopic Balloon Dilation Versus Endoscopic Stricturotomy for Short Strictures (< 3 cm) Related to Crohn's Disease (the BEST-CD Trial)
Crohn's disease (CD) related strictures can be treated endoscopically by endoscopic balloon dilation (EBD) or endoscopic stricturotomy (EST). EBD is is the established endoscopic treatment for short strictures in Crohn's disease. However, roughly half had recurrent symptoms and two third require surgery after EBD. ES have been used initially for endoscopic treatment of patients for whom EBD was unsuccessful. Subsequently it was shown that ES is a better modality for treating CD related strictures (specially short and anastomotic strictures) than EBD lowering the risk of future surgery and procedure related perforation albeit with an increased risk of bleeding. ES was shown to be non-inferior to re-do surgery in chronic pouch anastomotic sinus in ulcerative colitis (UC) and ileocolic anastomotic strictures in CD thus reducing surgical morbidity. However, these two modalities have not been compared in a randomized controlled manner. We aimed to compare the two endoscopic treatments with regard to clinical success, need for surgery or additional endoscopic procedure and safety in patients with CD who have short (<3 cm), predominantly fibrotic stenosis excluding those in the small bowel not accessible by endoscope/colonoscope.
Read the detailed description
Study design: Single centre, open-label, randomised trial to be done in Asian Institute of Gastroenterology, India Study population: All eligible consecutive patients with CD who developed de-novo or anastomotic strictures will be included.
Study settings:
The proposed study would be conducted in a high volume tertiary GI centre (Asian Institute of Gastroenterology) performing nearly more than 200 endoscopic balloon dilation :EBD/Endoscopic stricturotomy: ES procedures per year with an well established inflammatory bowel disease (IBD) registry with more than 7000 IBD patients under follow up.
The study will be conducted after approval by the institutional ethics committee. Written informed consent would be taken from each participants and the study would conform to the 1975 Declaration of Helsinki ethical guidelines.
Data collection: A survey administration software (google forms) would be used to collect the participant data (age, sex, ethnicity, clinical features, smoking status, details of CD diagnosis, disease phenotype, extra intestinal manifestations, family history, history of intestinal resection, details of stricture diagnosis, details of stricture: degree, number, location, radiological finding: concurrent abscess, fistula, enhancement; drug history for CD, procedural details: technical success, symptomatic improvement, endoscopic improvement, stricture related emergency visit or hospitalization, complications, subsequent need for additional endoscopic procedures or surgery upto a follow up of 1 year). Follow-up details would be collected via physical visit or telephonic communication.
Technique and instruments: Endoscopic balloon dilation (EBD) procedures will be performed with wire guided controlled radial expansion (CRE) pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 atmosphere (ATM) pressure. Balloon was inflated for at least 2 minutes and slowly deflated. For mild ooze post EBD, balloon tamponade will also done with the same balloon. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them. Additional EBD sessions would be considered as additional endoscopic procedure for the purpose of the study.
Endoscopic stricturotomy would be done using a needle knife/insulted tip (IT) knife with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3) as per by global interventional inflammatory bowel disease (IIBD) group consensus.
Definitions: Technical success for EBD was defined as ability to perform the EBD procedure. Scope passage after EBD/stricturotomy was assessed as a separate outcome which was defined as passage of endoscope through the area where EBD/ES was performed. This included colonoscope for colonic/pouch strictures, endoscope for upper GI and duodenal strictures and an enteroscope: motorized spiral or single balloon enteroscope for small bowel strictures except those in terminal ileum. Clinical success in EBD/ES was defined as clinical improvement in symptoms (pain/ intestinal, gastric outlet or colonic obstruction symptoms) after the procedure. Sustained clinical success was defined as absence of obstructive symptoms at 1 year follow up. Major adverse events were defined as perforation, bleeding requiring transfusion or any procedure related prolongation of hospitalization period or an endoscopic, radiologic or surgical intervention. Minor adverse events were bleeding not requiring blood transfusion, post procedural pain and any other self limiting complication (e.g., sore throat after spiral enteroscopy) which does not warrant prolongation of hospital stay. Adverse events will be recorded for all the patients; events were considered associated to be with the procedure when a causal association was possible, probable, or definite. Recurrence of symptoms would be defined as re-emergence of symptoms for which the procedure was initially performed.
Sample size Based on previous retrospective study, symptomatic improvement with EST and EBD (9.5% and 33.5% respectively, the estimated sample size is total 90 (45 in each group) keeping type 1 error as 0.05 and power as 80%.
Randomisation Patients will be randomly assigned (1:1) to receive either EBD (EBD group) or EST (EST group) using a digital en-block randomisation system (block size of four).
Data analysis Statistical analysis: Statistical analysis would be done by using statistical package for social sciences (SPSS, IBM: International Business machines, NY: New York, USA). Chi-square/Fisher's exact test was used to compare categorical variables and Mann-Whitney test would used to compare continuous variables between the two groups.P-value <0.05 would be considered statistically significant
Timeline: 3 years Recruitment of 100 CD patients with stenosis requiring EBD or EST over 2 years: follow up over 1 year.
Patient privacy An organised database for the purpose of this study will be formed based on google form with anonymised data set (i.e. name, address, and full post code will be removed, together with any other information which, in conjunction with other data held by or disclosed to the recipient, could identify the patient) which would be entered by clinical research assistant.
Study design Study type: Interventional (clinical trial) Estimated enrolment: 100 patients Allocation: Randomized Intervention model: Parallel assignment Masking: none (open label) Primary purpose: Therapeutic Official title: Randomized controlled trial comparing endoscopic balloon dilation versus endoscopic stricturotomy for short strictures (< 3 cm) related to Crohn's disease (the BEST-CD trial) Estimated start date : August - September 2022 (after ethical approval) Estimated recruitment completion: July - August 2023 Estimated study completion date: July - August 2023
- Conditions
- Crohn Disease
- Being tested
- Endoscopic balloon dilation, Endoscopic stricturotomy with or without stricturoplasty
- Keywords
- Endoscopic balloon dilation, Endoscopic stricturotomy, Crohn's disease
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endoscopic balloon dilationDevice
EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.
Endoscopic stricturotomy with or without stricturoplastyDevice
Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
| Study group | Role | What they receive |
|---|---|---|
| Endoscopic balloon dilation | Active comparator | Confirmed Crohn's disease with gastro-duodenal or ileo-colonic short (<3 cm) strictures (both de novo and anastomotic) without prior history of endoscopic stricture therapy Receives: Device: Endoscopic balloon dilation |
| Endoscopic stricturotomy with or without stricturoplasty | Active comparator | Confirmed Crohn's disease with gastro-duodenal or ileo-colonic short (<3 cm) strictures (both de novo and anastomotic) without prior history of endoscopic stricture therapy Receives: Device: Endoscopic stricturotomy with or without stricturoplasty |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of the percentage of sustained clinical improvement in EBD and ES arms
To compare sustained clinical improvement post EBD and ES (%) (time frame :
1year): percentage of patients having no obstructive symptoms due to CD related stenosis for which EBD/ES was performed for a period of 1 year
Measured: 1 year
Secondary outcomes (5)
Comparison of the percentage of patients requiring additional interventions in EBD and ES arms
To compare need for additional intervention (EBD/EST/Surgery) between EST and EBD arm (%) : the percentage of patients who require additional interventions for CD related stenosis over period of 1 year
Measured: 1 year
Comparison of percentage of technical success in EBD and ES arms
To compare technical success between EBD and ES (%): Percentage of patients in whom endoscope is passable after EBD/ES
Measured: During procedure
Comparison of the percentage of stricture related emergency department visits in EBD and ES arms
To compare stricture related visit to the emergency department after EST versus EBD: percentage of patients visiting the emergency department for CD stenosis related symptoms post EBD/ES over period of 1 year
Measured: 1 year
Comparison of the percentage of patients requiring stricture related hospitalizations in EBD and ES arms
To compare structure related hospitalization with EST versus EBD: percentage of patients visiting undergoing hospitalization for CD stenosis related symptoms post EBD/ES over period of 1 year
Measured: 1 year
Comparison of the percentage of procedure related complications related to EST versus EBD
To compare complications related to EST versus EBD as per American Society of Gastrointestinal Endoscopy (ASGE) lexicon for adverse seventh during endoscopy
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2022
- Study start10 Feb 2023
- Primary completion13 Apr 2025
- Study completion9 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Crohn DiseaseStudies of the same condition, open and under way.
- More trials run by Asian Institute of Gastroenterology, IndiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Asian Institute of Gastroenterology, India
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Partha Pal, MD, DNB, Principal investigator, Asian lnstitute of Gastroenterology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05521867
- Sponsor's protocol ID
- AIG/IEC-BH&R 32 / 07.2022-05
- Acronym
- BEST-CD
- Status last verified
- Jul 2025
- First submitted
- 28 Aug 2022
- Last updated
- 16 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pal P, Pooja K, Naaz SM, Marri UK, Rebala P, Gupta R, Rao GV, Tandan M, Reddy DN. Endoscopic Balloon Dilation Versus Endoscopic Stricturotomy for Short Crohn's Disease Strictures: The BEST-CD Randomized Trial. Clin Gastroenterol Hepatol. 2026 Oct 28:S1542-3565(26)00813-X. doi: 10.1016/j.cgh.2026.10.012. Online ahead of print.
PubMed 42950934
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Trial Comparing Endoscopic Balloon Dilation Versus Endoscopic Stricturotomy for Short Strictures (< 3 cm) Related to Crohn's Disease (the BEST-CD Trial)
- ClinicalTrials.gov ID
- NCT05521867
- Acronym / sponsor ID
- BEST-CD / AIG/IEC-BH&R 32 / 07.2022-05
- Conditions
- Crohn Disease
- Keywords
- Endoscopic balloon dilation, Endoscopic stricturotomy, Crohn's disease
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 96 participants (estimated)
- Lead sponsor
- Asian Institute of Gastroenterology, IndiaUniversity, hospital or other
- Study start
- 10 Feb 2023 (actual)
- Primary completion
- 13 Apr 2025 (actual)
- Study completion
- 9 Apr 2026 (estimated)
- First posted
- 30 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Crohn's disease (CD) related strictures can be treated endoscopically by endoscopic balloon dilation (EBD) or endoscopic stricturotomy (EST). EBD is is the established endoscopic treatment for short strictures in Crohn's disease. However, roughly half had recurrent symptoms and two third require surgery after EBD. ES have been used initially for endoscopic treatment of patients for whom EBD was unsuccessful. Subsequently it was shown that ES is a better modality for treating CD related strictures (specially short and anastomotic strictures) than EBD lowering the risk of future surgery and procedure related perforation albeit with an increased risk of bleeding. ES was shown to be non-inferior to re-do surgery in chronic pouch anastomotic sinus in ulcerative colitis (UC) and ileocolic anastomotic strictures in CD thus reducing surgical morbidity. However, these two modalities have not been compared in a randomized controlled manner. We aimed to compare the two endoscopic treatments with regard to clinical success, need for surgery or additional endoscopic procedure and safety in patients with CD who have short (<3 cm), predominantly fibrotic stenosis excluding those in the small bowel not accessible by endoscope/colonoscope.
Detailed description
Study design: Single centre, open-label, randomised trial to be done in Asian Institute of Gastroenterology, India Study population: All eligible consecutive patients with CD who developed de-novo or anastomotic strictures will be included.
Study settings:
The proposed study would be conducted in a high volume tertiary GI centre (Asian Institute of Gastroenterology) performing nearly more than 200 endoscopic balloon dilation :EBD/Endoscopic stricturotomy: ES procedures per year with an well established inflammatory bowel disease (IBD) registry with more than 7000 IBD patients under follow up.
The study will be conducted after approval by the institutional ethics committee. Written informed consent would be taken from each participants and the study would conform to the 1975 Declaration of Helsinki ethical guidelines.
Data collection: A survey administration software (google forms) would be used to collect the participant data (age, sex, ethnicity, clinical features, smoking status, details of CD diagnosis, disease phenotype, extra intestinal manifestations, family history, history of intestinal resection, details of stricture diagnosis, details of stricture: degree, number, location, radiological finding: concurrent abscess, fistula, enhancement; drug history for CD, procedural details: technical success, symptomatic improvement, endoscopic improvement, stricture related emergency visit or hospitalization, complications, subsequent need for additional endoscopic procedures or surgery upto a follow up of 1 year). Follow-up details would be collected via physical visit or telephonic communication.
Technique and instruments: Endoscopic balloon dilation (EBD) procedures will be performed with wire guided controlled radial expansion (CRE) pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 atmosphere (ATM) pressure. Balloon was inflated for at least 2 minutes and slowly deflated. For mild ooze post EBD, balloon tamponade will also done with the same balloon. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them. Additional EBD sessions would be considered as additional endoscopic procedure for the purpose of the study.
Endoscopic stricturotomy would be done using a needle knife/insulted tip (IT) knife with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3) as per by global interventional inflammatory bowel disease (IIBD) group consensus.
Definitions: Technical success for EBD was defined as ability to perform the EBD procedure. Scope passage after EBD/stricturotomy was assessed as a separate outcome which was defined as passage of endoscope through the area where EBD/ES was performed. This included colonoscope for colonic/pouch strictures, endoscope for upper GI and duodenal strictures and an enteroscope: motorized spiral or single balloon enteroscope for small bowel strictures except those in terminal ileum. Clinical success in EBD/ES was defined as clinical improvement in symptoms (pain/ intestinal, gastric outlet or colonic obstruction symptoms) after the procedure. Sustained clinical success was defined as absence of obstructive symptoms at 1 year follow up. Major adverse events were defined as perforation, bleeding requiring transfusion or any procedure related prolongation of hospitalization period or an endoscopic, radiologic or surgical intervention. Minor adverse events were bleeding not requiring blood transfusion, post procedural pain and any other self limiting complication (e.g., sore throat after spiral enteroscopy) which does not warrant prolongation of hospital stay. Adverse events will be recorded for all the patients; events were considered associated to be with the procedure when a causal association was possible, probable, or definite. Recurrence of symptoms would be defined as re-emergence of symptoms for which the procedure was initially performed.
Sample size Based on previous retrospective study, symptomatic improvement with EST and EBD (9.5% and 33.5% respectively, the estimated sample size is total 90 (45 in each group) keeping type 1 error as 0.05 and power as 80%.
Randomisation Patients will be randomly assigned (1:1) to receive either EBD (EBD group) or EST (EST group) using a digital en-block randomisation system (block size of four).
Data analysis Statistical analysis: Statistical analysis would be done by using statistical package for social sciences (SPSS, IBM: International Business machines, NY: New York, USA). Chi-square/Fisher's exact test was used to compare categorical variables and Mann-Whitney test would used to compare continuous variables between the two groups.P-value <0.05 would be considered statistically significant
Timeline: 3 years Recruitment of 100 CD patients with stenosis requiring EBD or EST over 2 years: follow up over 1 year.
Patient privacy An organised database for the purpose of this study will be formed based on google form with anonymised data set (i.e. name, address, and full post code will be removed, together with any other information which, in conjunction with other data held by or disclosed to the recipient, could identify the patient) which would be entered by clinical research assistant.
Study design Study type: Interventional (clinical trial) Estimated enrolment: 100 patients Allocation: Randomized Intervention model: Parallel assignment Masking: none (open label) Primary purpose: Therapeutic Official title: Randomized controlled trial comparing endoscopic balloon dilation versus endoscopic stricturotomy for short strictures (< 3 cm) related to Crohn's disease (the BEST-CD trial) Estimated start date : August - September 2022 (after ethical approval) Estimated recruitment completion: July - August 2023 Estimated study completion date: July - August 2023
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Endoscopic balloon dilation | Active comparator | Device: Endoscopic balloon dilationConfirmed Crohn's disease with gastro-duodenal or ileo-colonic short (<3 cm) strictures (both de novo and anastomotic) without prior history of endoscopic stricture therapy |
| Endoscopic stricturotomy with or without stricturoplasty | Active comparator | Device: Endoscopic stricturotomy with or without stricturoplastyConfirmed Crohn's disease with gastro-duodenal or ileo-colonic short (<3 cm) strictures (both de novo and anastomotic) without prior history of endoscopic stricture therapy |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (9 listed)
- No established diagnosis of CD;
- No endoscopic therapy; and
- A combination therapy of EST and EBD at the onset
- Small bowel CD related stricture requiring enteroscopy guided dilation
- Predominantly ulcerated strictures (mixed or pure ulcerated strictures)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endoscopic balloon dilationEBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them. | Device | Endoscopic balloon dilation |
| Endoscopic stricturotomy with or without stricturoplastyEndoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist. | Device | Endoscopic stricturotomy with or without stricturoplasty |
Primary outcome
Comparison of the percentage of sustained clinical improvement in EBD and ES arms
Time frame: 1 year
To compare sustained clinical improvement post EBD and ES (%) (time frame : 1year): percentage of patients having no obstructive symptoms due to CD related stenosis for which EBD/ES was performed for a period of 1 year
5 secondary outcomes
Comparison of the percentage of patients requiring additional interventions in EBD and ES arms
Time frame: 1 year
Comparison of percentage of technical success in EBD and ES arms
Time frame: During procedure
Comparison of the percentage of stricture related emergency department visits in EBD and ES arms
Time frame: 1 year
Comparison of the percentage of patients requiring stricture related hospitalizations in EBD and ES arms
Time frame: 1 year
Comparison of the percentage of procedure related complications related to EST versus EBD
Time frame: 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2025.
- Derived from this study: PubMed 42950934Pal P, Pooja K, Naaz SM, Marri UK, Rebala P, Gupta R, Rao GV, Tandan M, Reddy DN. Endoscopic Balloon Dilation Versus Endoscopic Stricturotomy for Short Crohn's Disease Strictures: The BEST-CD Randomized Trial. Clin Gastroenterol Hepatol. 2026 Oct 28:S1542-3565(26)00813-X. doi: 10.1016/j.cgh.2026.10.012. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Crohn Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Partha Pal, MD, DNB principal investigator
Asian lnstitute of Gastroenterology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Endoscopic balloon dilation and Endoscopic stricturotomy with or without stricturoplasty in people with Crohn Disease, run by Asian Institute of Gastroenterology, India at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of the percentage of sustained clinical improvement in EBD and ES arms (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05521867, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2025.